Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG

Prostate cancer (PCa) is a major health concern, being the second most common diagnosed cancer worldwide, and the fifth leading cause of cancer death in men (American Cancer Society, 2015). Most patients are diagnosed with localized disease. Some of these patients will eventually present with disease progression, and develop metastatic disease, for which the mainstay of treatment is androgen deprivation therapy (ADT) (Mottet et al., 2017). Despite initial responses, almost all men with metastatic disease will progress to metastatic castration-resistant prostate cancer (mCRPC).

Source: Critical Reviews in Oncology Hematology - December 30, 2017 Category: Cancer & Oncology Authors: Jean-Baptiste Beauval, Yohann Loriot, Christophe Hennequin, Fran çois Rozet, Philippe Barthelemy, Delphine Borchiellini, Friederike Schlürmann Constans, Emmanuel Gross, Denis Maillet, Gilles Pasticier, Géraldine Pignot, Marc-Olivier Timsit, Sébastien Source Type: research